Why the Biden administration might not want to be content with just an acting FDA commissioner
Another month has passed without President Joe Biden nominating anyone to fill the permanent FDA commissioner position, and experts are continuing to raise concerns about what it means for the agency to not have a Senate-approved leader during a once-in-a-lifetime pandemic.
The push to fill the top spot at the FDA once seemed like a two-person race between acting commissioner Janet Woodcock, an industry and FDA insider favorite who has ruffled some feathers among Senate Democrats, and former principal deputy commissioner of FDA Josh Sharfstein, who’s now a vice dean and professor at Johns Hopkins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.